COVID-19 pneumonia is a lung infection caused by the SARS-CoV-2 virus that can lead to inflammation and fluid in the lungs. It ranges from mild illness to severe respiratory failure and may require hospitalization or intensive care.
FDA approves Genentech's Tecentriq as first ctDNA-guided adjuvant therapy for muscle-invasive bladder cancer, and Venclexta plus acalabrutinib as first all-oral fixed-duration regimen for CLL.
The FDA approved acalabrutinib plus venetoclax for previously untreated CLL/SLL based on phase 3 AMPLIFY data. The fixed 14-month regimen improved progression-free survival versus chemotherapy.
The FDA has approved a supplemental new drug application for the combination regimen of Venclexta (venetoclax) and acalabrutinib for previously untreated adult patients with chronic lymphocytic leukemia, supported by Phase 3 AMPLIFY trial data.
The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration regimen for previously untreated chronic lymphocytic leukemia, based on phase III AMPLIFY trial results showing 35% reduction in disease progression or death risk versus chemoimmunotherapy.
The FDA has approved the combination of Venclexta (venetoclax) plus acalabrutinib as the first all-oral, fixed-duration regimen for previously untreated adults with chronic lymphocytic leukemia, based on Phase III AMPLIFY study results.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07213518 |
High Velocity Nasal Insufflation Versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients |
COMPLETED | NA |
| NCT07154212 |
Hepatitis B Virus Reactivation in COVID-19 |
COMPLETED | |
| NCT06927622 |
Corona Virus Disease 2019 Cohort Study |
RECRUITING | |
| NCT06677658 |
The Role of Olive Oil in the Treatment of Covid-19 Pneumonia |
COMPLETED | |
| NCT06601998 |
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19. |
RECRUITING | |
| NCT06501599 |
AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes |
RECRUITING | |
| NCT06402318 |
Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine |
RECRUITING | |
| NCT06272266 |
The Aerobic Exercise Capacity and Muscle Strenght in Individuals With COVID-19 |
COMPLETED | NA |
| NCT06156137 |
Characteristics of Blood Glucose Variability in Patients With Type 2 Diabetes Mellitus and COVID-19 |
RECRUITING | |
| NCT06113757 |
Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease |
COMPLETED | NA |
